QUADRO 试验:四联与三联单片复方制剂治疗难治性高血压的比较
QUADRO 为多中心、3 期、随机、双盲试验,纳入 183 例难治性高血压患者,在 8 周培哚普利/吲达帕胺/氨氯地平导入期后,1:1 随机接受四联单片复方制剂(加比索洛尔)或继续三联治疗 8 周。结果显示四联组诊室收缩压和 24 小时动态血压降幅均大于三联组,两种治疗均耐受良好。
要点
- 四联单片复方制剂较三联治疗进一步降低诊室收缩压约 8 mmHg。
- 24 小时动态血压降幅同样支持四联方案优于三联方案。
- 四联方案耐受良好,未报告严重或重度治疗中出现的不良事件。
核心结论
- 首个全剂量四联降压单片复方制剂(培哚普利/吲达帕胺/氨氯地平/比索洛尔)在确证难治性高血压中优于培哚普利/吲达帕胺/氨氯地平三联治疗。
研究设计与样本
- QUADRO 为多中心、3 期、随机、对照、双盲试验,纳入难治性高血压患者 183 例(四联组 89 例,三联组 94 例)。
- 经 8 周培哚普利/吲达帕胺/氨氯地平导入期后,1:1 随机接受四联单片复方制剂或继续三联治疗 8 周。
- 主要疗效指标为第 8 周诊室收缩压,同时评估 24 小时动态血压监测。
主要发现
- 第 8 周时,四联组诊室收缩压降幅较三联组多降低 8 mmHg(95%CI:-11.99 至 -4.09;P < .0001)。
- 第 8 周时,四联组 24 小时动态血压降幅较三联组多降低 8 mmHg(95%CI:-10.95 至 -4.11;P < .0001)。
- 四联组 10 例(11%)和三联组 8 例(8%)发生至少一次治疗中出现的不良事件,未报告严重或重度不良事件。
关键数值与推荐
- 难治性高血压定义为三联治疗(培哚普利/吲达帕胺/氨氯地平)8 周后血压仍未控制。
- 主要疗效分析纳入所有随机且收缩压未控制的患者。
临床怎么用
- 对于经三联治疗血压仍未控制的难治性高血压患者,可考虑换用含比索洛尔的全剂量四联单片复方制剂以进一步降压。
- 四联单片复方制剂在该试验中耐受良好,可作为确证难治性高血压的有效治疗选择。
局限性
- 样本量较小(共 183 例),随访时间较短(8 周)。
- 结果仅基于单一四联单片复方制剂方案,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: True resistant hypertension leads to higher rates of target-organ damage, cardiovascular morbidity, and mortality compared with general hypertension. Guidelines recommend adding a fourth drug to triple therapy if blood pressure (BP) remains uncontrolled. This Phase 3 trial aimed to demonstrate superior BP reduction with the first full-dose quadruple single-pill combination (SPC) vs triple antihypertensive therapy for uncontrolled BP. METHODS: QUADRO was a multicentre, Phase 3, randomized, controlled, double-blind trial in resistant hypertension. After an 8-week run-in period on perindopril/indapamide/amlodipine, participants were randomized 1:1 to quadruple SPC perindopril/indapamide/amlodipine/bisoprolol or continued the same triple therapy for 8 weeks. Efficacy assessments included office systolic BP (SBP) at Week 8 (primary outcome) and 24 h ambulatory BP monitoring (ABPM). The primary analysis examined all randomized patients with uncontrolled SBP; safety analyses included all patients who received at least one dose of study medication. This trial is registered under EudraCT No. 2020-004891-16. RESULTS: Overall, 183 patients (quadruple SPC, n = 89; triple therapy, n = 94) were randomized. After 8 weeks, decreases in office SBP [-8 mmHg; 95% confidence interval (CI): -11.99, -4.09; P < .0001] and 24 h-ABPM (-8 mmHg; 95% CI: -10.95, -4.11; P < .0001) were greater with quadruple SPC vs triple therapy. Both treatments were well tolerated; 10 participants (11%) receiving quadruple SPC and 8 (8%) receiving triple therapy had at least one treatment-emergent adverse event (TEAE), and no serious or severe TEAEs were reported. CONCLUSIONS: The first full-dose quadruple antihypertensive SPC (perindopril/indapamide/amlodipine/bisoprolol) demonstrated superiority over perindopril/indapamide/amlodipine, offering an effective alternative therapy for confirmed resistant hypertension.
引用
- Taddei S, Narkiewicz K, Bricout-Hennel S, et al. Quadruple vs triple therapy for resistant hypertension: the QUADRO trial. Eur Heart J. 2026. PMID: 41667119. doi:10.1093/eurheartj/ehag022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。